A statement of changes in beneficial ownership for Oaktree Specialty Lending Corp (NASDAQ:OCSL) was filed on August 13, 2026, disclosing a purchase of common stock by Chief Executive Officer and Co-Chief Investment Officer Armen Panossian on August 12, 2026.
A Form 4 filed with the SEC on August 13, 2026, discloses that Michael V. Schrock, a director of Plexus Corp (NASDAQ:PLXS), sold 4,000 shares of common stock on August 11, 2026, pursuant to a pre-established Rule 10b5-1 trading plan.
A Form 4 filed on August 13, 2026 discloses that Stephen W. Beard, Chairman and CEO of Covista Inc. (NYSE American:CVSA), sold 3,545 shares of common stock on August 11, 2026 pursuant to a pre-established Rule 10b5-1 trading plan.
A Form 4 filed on August 13, 2026, disclosed that Adam R. Craig, Executive Chairman and Director of X4 Pharmaceuticals, Inc. (NASDAQ:XFOR), sold 47,436 shares of common stock on August 12, 2026, to cover personal income tax obligations arising from the settlement of a …
John Volpone, President of X4 Pharmaceuticals, Inc. (NASDAQ:XFOR), filed a Form 4 on August 13, 2026, disclosing the sale of 24,576 shares of common stock on August 12, 2026, to cover a personal income tax obligation upon settlement of a restricted stock unit award.
Michael D. Shafer, Executive Vice President at Thermo Fisher Scientific Inc., filed a Form 4 with the SEC on August 13, 2026, disclosing stock option exercises and sales of common stock that took place on August 11, 2026.
Sarbani Chaudhuri, Chief Commercial and Medical Affairs Officer of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT), filed a statement of changes in beneficial ownership on August 13, 2026, reporting a sale of common stock on August 11, 2026.
Christopher James Stevens, Chief Operating Officer of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT), filed a statement of changes in beneficial ownership on August 13, 2026, reporting a sale of common stock on August 11, 2026, in connection with the vesting of restricted stock units.
Ahmet Tezel, Chief Innovation Officer of LivaNova PLC (NASDAQ:LIVN), filed a Form 4 on August 13, 2026, reporting multiple transactions in the company's ordinary shares on August 11, 2026.
A Form 4 filed on August 13, 2026, discloses that Jorge Mas, a director of MasTec Inc. (NYSE:MTZ), entered into a fourth amendment to an existing prepaid variable forward sale contract covering 1,099,335 shares of MasTec common stock, with the transaction dated August 11, …